前梯度蛋白2(AGR2)重組蛋白
Recombinant Anterior Gradient 2 (AGR2)
GOB4; HAG2; XAG2; AG2; PDIA17; HPC8; Anterior Gradient Protein 2; Protein Disulfide Isomerase Family A,Member 17; Secreted cement gland protein XAG-2 homolog
- 編號RPC285Mu01
- 物種Mus musculus (Mouse，小鼠)相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位分泌
- 預測分子量24.6kDa
- 實際分子量25kDa(差異分析請參閱說明書)
- 片段與標簽Lys21~Leu175 with N-terminal His Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性狀凍干粉
- 純度> 90%
- 等電點6.9
- 應用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價格¥ 864¥ 2160¥ 4320¥ 12960¥ 32400
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Figure . Gene Sequencing (extract)
Figure. SDS-PAGE
通過ISO 9001、ISO 13485質量體系認證
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPC285Mu01 | 前梯度蛋白2(AGR2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC285Mu01 | 前梯度蛋白2(AGR2)多克隆抗體 | WB; IHC; ICC; IP. |
| LAC285Mu71 | 前梯度蛋白2(AGR2)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| SEC285Mu | 前梯度蛋白2(AGR2)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| KSC285Mu01 | 前梯度蛋白2(AGR2)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | 自己動手制作ELISA試劑盒的主要材料 |
參考文獻
| 雜志 | 參考文獻 |
| Cancer Biomarkers | Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma[MetaPress: n7137r6271u54118] |
| Molecular & Cellular Proteomics | Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers[PubMed: PMC3205865] |
| Prostate. | Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype[Pubmed: 22911164] |
| BMC Cancer. | Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9[Pubmed: 24007603] |
| Clinical Cancer Research | Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer[Pubmed:25239611] |
| PLoS One | AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection[PubMed: 25875093] |
| Clinical Neurology and Neurosurgery | Serum AGR2 as a useful biomarker for pituitary adenomas[S0303846717300045] |
| Oncotarget | Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2)[Pubmed:29937991] |
| Int J Oncol | Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapy?induced senescence escape[34913074] |
| International Journal of Cancer | Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer[Pubmed:35689436] |